Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. Warning Letter
  6. /
  7. Baxter Biosciences
WARNING LETTER
•Baxter Biosciences•October 19, 2009

Baxter Biosciences – FDA Warning Letter, Oct 19, 2009

Record Details

The FDA issued a Warning Letter to Baxter Healthcare Corporation following an inspection of its Lessines, Belgium facility from October 12-19, 2009. The inspection revealed significant deviations from current Good Manufacturing Practice (CGMP) in the manufacture of Gammagard Liquid and Gammagard S/D intermediates, violating Section 501(a)(2)(B) of the FD&C Act, Section 351(a) of the PHS Act, and 21 CFR Part 601.

Key violations include: 1. **Incomplete Failure Investigations:** Recurrent clogging of filters in Gammagard Liquid production, attributed to (b)(4), was not adequately investigated. Approximately 107 lots experienced clogging since January 2008, with 106 for US distribution, and 78 shipped. Impacted lots were not placed on stability, and corrective actions were not implemented, with 42% of 2009 lots still experiencing clogging. 2. **Failure to Follow Procedures:** The company failed to follow SOP LE-09-FT03076 for initiating exception reports for filter replacement events, even after the procedure was revised to allow more filter changes. 3. **Production and Process Controls:** Validation of the Solvent/Detergent (S/D) viral inactivation step lacked data for effectiveness with (b)(4)

Company
Baxter Biosciences
Inspection date
October 19, 2009
Product type
Biologics
Office
Center for Biologics Evaluation and Research
People
  • Mary A. Malarkey (Director - - Ex-FDA)
  • Valerie De Schutter
View Company Profile

ID · 8005070a-fad5-4041-82af-eb599751b432

Violation Codes2
FD&C Act 501(a)(2)(B)21 CFR 601.12

Full citation text and observation details available on the Dashboard.

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Baxter Biosciences
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.